Nosratola D Vaziri Selected Research

Chylomicron Remnants

4/2014	Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.
1/2013	Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
1/2011	Lipid disorders and their relevance to outcomes in chronic kidney disease.
9/2010	Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
11/2009	Causes of dysregulation of lipid metabolism in chronic renal failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nosratola D Vaziri Research Topics

Disease

98	Inflammation (Inflammations) 02/2021 - 02/2003
73	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 09/2001
62	Chronic Renal Insufficiency 02/2021 - 09/2001
61	Hypertension (High Blood Pressure) 12/2019 - 01/2002
44	Proteinuria 01/2021 - 01/2002
37	Fibrosis (Cirrhosis) 11/2022 - 09/2004
20	Anemia 01/2020 - 05/2004
19	Atherosclerosis 08/2014 - 09/2004
18	Cardiovascular Diseases (Cardiovascular Disease) 02/2021 - 05/2004
18	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2021 - 01/2002
17	Hypercholesterolemia 04/2014 - 05/2002
15	Kidney Diseases (Kidney Disease) 01/2021 - 04/2004
15	Hypertriglyceridemia 01/2021 - 01/2002
13	Azotemia 08/2013 - 11/2005
12	Hyperlipidemias (Hyperlipidemia) 01/2021 - 01/2002
11	Hypoalbuminemia 01/2021 - 05/2002
11	Renal Insufficiency (Renal Failure) 01/2019 - 01/2002
11	Uremia 12/2017 - 01/2010
10	Obesity 01/2021 - 03/2002
10	Body Weight (Weight, Body) 01/2019 - 03/2002
9	Dysbiosis 01/2021 - 01/2017
9	Dyslipidemias (Dyslipidemia) 01/2021 - 05/2010
8	Iron Overload 07/2019 - 04/2012
7	Insulin Resistance 02/2021 - 10/2004
6	Cachexia 01/2021 - 12/2010
5	Hyperphosphatemia 01/2019 - 01/2011
5	Ischemia 01/2019 - 02/2005
5	Type 2 Diabetes Mellitus (MODY) 01/2014 - 01/2013
5	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 08/2013 - 01/2002
4	Ureteral Obstruction 10/2022 - 07/2009
4	Neoplasms (Cancer) 02/2021 - 07/2007

Drug/Important Bio-Agent (IBA)

39	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2001
35	AntioxidantsIBA 04/2020 - 09/2001
31	LipidsIBA 01/2019 - 03/2002
24	CholesterolIBA 01/2018 - 05/2002
22	CreatinineIBA 01/2020 - 01/2002
21	EnzymesIBA 04/2020 - 01/2003
21	IronIBA 01/2020 - 05/2004
21	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 09/2001
18	HDL LipoproteinsIBA 01/2016 - 05/2003
17	Urea (Carbamide)FDA LinkGeneric 01/2021 - 01/2006
17	NF-kappa B (NF-kB)IBA 01/2019 - 01/2004
17	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2016 - 01/2002
16	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2008
16	Lipoproteins (Lipoprotein)IBA 01/2018 - 03/2002
16	oxidized low density lipoproteinIBA 10/2016 - 03/2002
14	NADPH Oxidases (NAD(P)H oxidase)IBA 06/2014 - 01/2003
12	Triglycerides (Triacylglycerol)IBA 01/2016 - 03/2002
12	Superoxide DismutaseIBA 06/2014 - 01/2003
11	Uremic ToxinsIBA 02/2021 - 01/2014
11	Nitric Oxide Synthase (NO Synthase)IBA 01/2018 - 09/2001
11	VLDL LipoproteinsIBA 01/2016 - 01/2002
11	3-nitrotyrosineIBA 01/2012 - 09/2001
10	HDL CholesterolIBA 10/2019 - 03/2002
10	Fatty Acids (Saturated Fatty Acids)IBA 07/2017 - 07/2004
10	LDL Lipoproteins (beta Lipoproteins)IBA 01/2016 - 07/2004
9	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2019 - 02/2009
9	EndotoxinsIBA 11/2017 - 01/2012
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 11/2004
8	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2021 - 01/2002
8	Glutathione PeroxidaseIBA 04/2020 - 01/2003
8	Phosphates (Orthophosphate)IBA 01/2020 - 01/2011
8	Erythropoietin FDA Link 01/2020 - 05/2004
8	Angiotensin IIIBA 01/2018 - 06/2002
8	CatalaseIBA 05/2015 - 01/2003
8	LDL Receptors (LDL Receptor)IBA 04/2014 - 07/2003
7	Adenine FDA LinkGeneric 10/2022 - 01/2012
7	CateninsIBA 09/2019 - 01/2017
7	TriterpenesIBA 02/2018 - 01/2013
7	CarbohydratesIBA 01/2017 - 03/2002
7	SaltsIBA 06/2014 - 03/2003
6	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 11/2022 - 01/2019
6	Resistant StarchIBA 11/2020 - 01/2014
6	AmmoniaIBA 01/2017 - 01/2013
6	Interleukin-6 (Interleukin 6)IBA 10/2016 - 12/2005
6	bardoxolone methylIBA 01/2014 - 10/2012
6	Insulin (Novolin)FDA Link 01/2013 - 07/2002
6	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 01/2013 - 05/2002
5	Dimethyl FumarateIBA 01/2021 - 01/2014
5	Pharmaceutical PreparationsIBA 01/2020 - 08/2007
5	ferric citrateIBA 01/2020 - 01/2016
5	HematinicsIBA 07/2019 - 04/2012
5	Transcription Factors (Transcription Factor)IBA 01/2019 - 10/2005
5	ReninIBA 01/2018 - 06/2002
5	IDL Lipoproteins (Lipoprotein, IDL)IBA 01/2016 - 09/2010
5	LDL CholesterolIBA 04/2014 - 03/2002
5	Chylomicron RemnantsIBA 04/2014 - 11/2009
5	ChylomicronsIBA 04/2014 - 03/2005
5	AngiotensinsIBA 10/2012 - 10/2006
5	Glutathione (Reduced Glutathione)IBA 08/2011 - 03/2002
5	Liver X ReceptorsIBA 10/2010 - 01/2009
5	VLDL receptorIBA 11/2009 - 01/2002
5	Superoxides (Superoxide)IBA 01/2009 - 01/2003
5	Cholesterol 7-alpha-Hydroxylase (Cholesterol 7 alpha Hydroxylase)IBA 12/2005 - 05/2002
4	Glucose (Dextrose)FDA LinkGeneric 02/2021 - 01/2003

Therapy/Procedure

34	Therapeutics 01/2021 - 09/2001
24	Renal Dialysis (Hemodialysis) 01/2021 - 04/2009
7	Nephrectomy 07/2020 - 10/2009
5	Diet Therapy (Therapy, Diet) 02/2019 - 08/2002
5	Peritoneal Dialysis 01/2019 - 01/2013